Pfizer Caduet Launch Set For May; Inspra Starts Slow

Pfizer will position the Lipitor/Norvasc combination product Caduet as an "upgrade" for the vast majority of hypertension patients, rather than focus on cannibalizing Norvasc, the company told analysts during an April 20 earnings conference call